MedTrace Logo

Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients

NCT05688046 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2023-01-19

No results posted yet for this study

Summary

Immune checkpoint inhibitors(ICIs) combined with angiogenesis inhibitors may is synergistic in elderly patients with advanced non-small cell lung cancer(NSCLC), however its true efficacy is still unclear. The investigators retrospectively compared clinical efficacy and safety of driver-negative elderly patients with advanced NSCLC treated with ICIs with(or without)angiogenesis inhibitors in the Cancer Center of the Affiliated Suzhou Hospital of Nanjing Medical University.

Conditions

Interventions

DRUG

Immune checkpoint inhibitors plus angiogenesis inhibitors

PD-(L)1-based therapy plus Bevacizumab or Anlotinib

DRUG

Immune checkpoint inhibitors without angiogenesis inhibitors

PD-(L)1-based therapy

Sponsors & Collaborators

  • Suzhou Municipal Hospital

    lead OTHER

Principal Investigators

  • Jing Xue · The Affiliated Suzhou Hospital of Nanjing Medical University

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-08-01
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05688046 on ClinicalTrials.gov